主页 > 医学新闻 >
【drug-news】FDA 批准Medtronic年龄针对7-17岁的葡萄糖
FDA approves Medtronic glucose monitoring products for ages 7-17
MDT49.25, -0.39, -0.8%) said the Food and Drug Administration approved its Real-Time continuous glucose monitoring devices for ages 7 to 17 years old.
Previously, the diabetes monitoring products were approved only for adult patients, the Minneapolis maker of implantable biomedical devices said Monday.
The company said the Real-Time continuous glucose monitoring system will soon be available in pediatric models of the MiniMed Paradigm Real-Time System and Guardian Real-Time System. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领
我是新手,先领个小的 FDA approves Medtronic glucose monitoring products for ages 7-17
FDA 批准Medtronic针对7-17岁年龄的葡萄糖监测产品
MDT49.25, -0.39, -0.8%) said the Food and Drug Administration approved its Real-Time continuous glucose monitoring devices for ages 7 to 17 years old.
据报道，美国食品与药品管理局批准了（Medtronic) 针对7-17岁年龄的实时持续葡萄糖监测产品
Previously, the diabetes monitoring products were approved only for adult patients, the Minneapolis maker of implantable biomedical devices said Monday.
周一，生产可植入性生物医药设备的Minnespolis公司称以前只批准针对成人的糖尿病监测产品。
The company said the Real-Time continuous glucose monitoring system will soon be
available in pediatric models of the MiniMed Paradigm Real-Time System and Guardian Real-Time System.
Minnespolis公司称实时持续葡萄糖监测系统将迅速运用于幼年实时系统中的儿科病人和成人实时系统
编译-----试试看
FDA 批准Medtronic公司针对7-17岁年龄的葡萄糖监测产品
据市场观察网站的新闻报道，美国食品与药品管理局批准了Medtronic公司 针对7-17岁年龄的实时持续葡萄糖监测产品。本周一，生产可植入性生物医药设备的Minnespolis公司称以前FDA只批准针对成人的糖尿病监测产品。现在此产品批准后，实时持续葡萄糖监测系统将迅速运用于成人实时系统和幼年实时系统中的儿科病人。
请大家多多指教！！ 仅供参考:
1. Medtronic, Inc. 美国美敦力公司
2.Minnespolis 明尼阿波利斯 ，地名，是 Medtronic, Inc.总部所在地，位于美国明尼苏达州
3. The MiniMed Paradigm REAL-Time System： CGM +insulin pump
The Guardian REAL-Time System： a stand-alone CGM device
已经获得FDA批准 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-28 05:11
医学,生命科学网